Ipsen S.A. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Ipsen S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Ipsen S.A. - Product Pipeline Review - 2014', provides an overview of the Ipsen S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ipsen S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ipsen S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ipsen S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ipsen S.A.'s pipeline products

Reasons to buy

- Evaluate Ipsen S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ipsen S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ipsen S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ipsen S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ipsen S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ipsen S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Ipsen S.A. Snapshot 7
Ipsen S.A. Overview 7
Key Information 7
Key Facts 7
Ipsen S.A. - Research and Development Overview 8
Key Therapeutic Areas 8
Ipsen S.A. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Ipsen S.A. - Pipeline Products Glance 18
Ipsen S.A. - Late Stage Pipeline Products 18
Phase III Products/Combination Treatment Modalities 18
Ipsen S.A. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Ipsen S.A. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Ipsen S.A. - Drug Profiles 23
abobotulinumtoxinA 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
abobotulinumtoxinA next generation 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lanreotide acetate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
triptorelin pamoate XR 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BN-82451 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
taspoglutide 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BIM-46187 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Inhibit 17Beta-HSDs Type 1 For Breast and Prostate Cancer 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Recombinant Protein-1 To Inhibit SNARE For Neurology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Recombinant Protein-2 To Inhibit SNARE For Neurology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Proteins to Agonize Growth Hormone Receptor for Growth Disorders 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Recombinant Proteins to Antagonize Growth Hormone Receptor for Acromegaly 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
STX-140 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
STX-2171 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
STX-681 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SXN-101742 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SXN-101959 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Synthetic Peptides to Agonize GIPR for Metabolic Disorders 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BIM-23-A-758 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Drug to Antagonize Androgen Receptor 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Peptides for Endocrine Disease 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptides to Antagonize ACTH Receptor for Cushing Syndrome 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recombinant Protein Targeting 1 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Recombinant Protein Targeting 2 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Recombinant Proteins to Agonize IGF-1 for Diabetes 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Moleucles to Inhibit Aromatase and Steroid Sulphatase for Breast Cancer 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Ipsen S.A. - Pipeline Analysis 54
Ipsen S.A. - Pipeline Products by Target 54
Ipsen S.A. - Pipeline Products by Route of Administration 56
Ipsen S.A. - Pipeline Products by Molecule Type 57
Ipsen S.A. - Pipeline Products by Mechanism of Action 58
Ipsen S.A. - Recent Pipeline Updates 60
Ipsen S.A. - Dormant Projects 65
Ipsen S.A. - Discontinued Pipeline Products 66
Discontinued Pipeline Product Profiles 66
BIM-23A760 66
(mecasermin + somatropin) 66
cicletanine 66
irosustat 66
Ipsen S.A. - Company Statement 67
Ipsen S.A. - Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
Ipsen S.A., Key Information 7
Ipsen S.A., Key Facts 7
Ipsen S.A. - Pipeline by Indication, 2014 10
Ipsen S.A. - Pipeline by Stage of Development, 2014 12
Ipsen S.A. - Monotherapy Products in Pipeline, 2014 13
Ipsen S.A. - Partnered Products in Pipeline, 2014 14
Ipsen S.A. - Partnered Products/ Combination Treatment Modalities, 2014 15
Ipsen S.A. - Out-Licensed Products in Pipeline, 2014 16
Ipsen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Ipsen S.A. - Phase III, 2014 18
Ipsen S.A. - Phase II, 2014 19
Ipsen S.A. - Phase I, 2014 20
Ipsen S.A. - Preclinical, 2014 21
Ipsen S.A. - Discovery, 2014 22
Ipsen S.A. - Pipeline by Target, 2014 55
Ipsen S.A. - Pipeline by Route of Administration, 2014 56
Ipsen S.A. - Pipeline by Molecule Type, 2014 57
Ipsen S.A. - Pipeline Products by Mechanism of Action, 2014 59
Ipsen S.A. - Recent Pipeline Updates, 2014 60
Ipsen S.A. - Dormant Developmental Projects,2014 65
Ipsen S.A. - Discontinued Pipeline Products, 2014 66
Ipsen S.A., Subsidiaries 68